Sutro Biopharma STRO Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's deferred revenue?
- Sutro Biopharma (STRO) reported deferred revenue of $9.4M in Q1 2026.
- How has Sutro Biopharma's deferred revenue changed year-over-year?
- Sutro Biopharma's deferred revenue decreased by 86.4% year-over-year, from $68.98M to $9.4M.
- What is the long-term trend for Sutro Biopharma's deferred revenue?
- Over 5 years (2020 to 2025), Sutro Biopharma's deferred revenue has grown at a -6.3% compound annual growth rate (CAGR), from $14.6M to $10.56M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.